Pedram Razavi

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-04-18

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-03-26 · 2 citations

• Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

  Nature · 2026-03-04 · 4 citations

• A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancer

  ESMO Open · 2026-03-01

• PS5-09-20: A global Phase III, randomized, double-blind trial of BNT327 plus chemotherapy (chemo) vs placebo plus chemo in patients (pts) with previously untreated locally recurrent inoperable or metastatic, PD-L1 negative triple negative breast cancer (TNBC) (ROSETTA Breast-01)

  Clinical Cancer Research · 2026-02-17

• Supplementary Figures S1-S3 from Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding

  2026-02-09

• Supplementary Figures S1-S3 from Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding

  2026-02-06

• Data from Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding

  2026-02-06

• Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer

  Breast Cancer Research · 2026-01-31 · 1 citations

• Publisher Correction: APOBEC3 mutagenesis drives therapy resistance in breast cancer

  Nature Genetics · 2025-12-12 · 1 citations

• Supplementary Figure from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

  2025-12-09

• Supplementary Data from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

  2025-12-09

• Tracking ongoing chromosomal instability using single-cell whole-genome sequencingPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-27 · 3 citations

• Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding

  Cancer Discovery · 2025-11-10 · 18 citations

• Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data

  Clinical Cancer Research · 2025-11-10 · 3 citations

• The AI revolution: how multimodal intelligence will reshape the oncology ecosystem

  npj Artificial Intelligence · 2025-11-07 · 6 citations

• Fragmentomics enhances tumor-naïve aneuploidy detection from plasma whole genome sequencing

  The Journal of Liquid Biopsy · 2025-11-01

• A RANDOMIZED PHASE III STUDY OF FIRST-LINE SARUPARIB (AZD5305) + CAMIZESTRANT VS CDK4/6I + PHYSICIAN’S CHOICE ENDOCRINE THERAPY OR CDK4/6I + CAMIZESTRANT IN PTS WITH HR+/HER2- ADVANCED BREAST CANCER WITH BRCA1/ BRCA2/PALB2 MUTATIONS (EVOPAR-BREAST01)

  The Breast · 2025-11-01

• 405P Optimizing prognostic models for early breast cancer (EBC) recurrence using real-world data (RWD) and machine learning (ML)

  ESMO Real World Data and Digital Oncology · 2025-11-01

• Predictors of response to neoadjuvant chemo-immunotherapy in metaplastic triple-negative breast cancer

  npj Breast Cancer · 2025-10-02 · 3 citations